Supernus Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

Supernus Pharmaceuticals

05/08/2025 22:02

Supernus Pharmaceuticals Inc SUPN.OQ reported quarterly adjusted earnings of 40 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of 77 cents.  The mean expectation of five analysts for the quarter was for earnings of 47 cents per share. Wall Street expected results to range from 41 cents to 52 cents per share.

Revenue fell 6.1% to $158.00 million from a year ago; analysts expected $154.06 million.

Supernus Pharmaceuticals Inc shares had risen by 17.5% this quarter and gained 2.5% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 1.4% in the last three months.​

In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Supernus Pharmaceuticals Inc is $40.00, about 7.4% above its last closing price of $37.05

This summary was machine generated from LSEG data August 5 at 09:02 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
0.47
0.40
Missed
Mar. 31 2025
0.37
0.44
Beat
Dec. 31 2024
0.42
0.75
Beat
Sep. 30 2024
0.44
1.17
Beat